Document Detail

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
MedLine Citation:
PMID:  23014186     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: Many antihuman epidermal growth factor receptor (anti-HER2)-targeted agents, covering a broad spectrum of mechanisms of action, have been recently developed. The concept of dual anti-HER2 blockade has been preclinically and clinically assessed with positive results. In this article, the authors review the biologic rationale for dual HER2 blockade, along with the clinical findings.
RECENT FINDINGS: Dual anti-HER2 blockade has been assessed in the metastatic setting, including with chemotherapy-free regimens, leading to impressive responses, even in heavily pretreated patients. In the neoadjuvant setting, dual anti-HER2 blockade combinations and chemotherapy have almost doubled the rates of pathologic complete response compared to single anti-HER2 therapy. Similar strategies are now actively being pursued in the adjuvant setting and, it is hoped, will improve the outcome of many patients with HER2-positive breast cancer.
SUMMARY: Combining different anti-HER2-targeted agents represents a promising therapeutic strategy, now reaching clinical practice. There are major clinical challenges yet to be resolved, rising from the increasing number of potential combinations and their mechanisms of resistance. Smartly designed clinical trials are required to address these challenges and perhaps to define a subset of patients that can be spared chemotherapy.
Dimitrios Zardavas; Ivana Bozovic-Spasojevic; Evandro de Azambuja
Related Documents :
23341716 - Early response to bortezomib combined chemotherapy can help predict survival in patient...
25081726 - A predictive model for evaluating responsiveness to pemetrexed treatment in patients wi...
24935356 - Ercc1 as a biological marker guiding management in malignant pleural mesothelioma.
19757306 - Exploring mammalian target of rapamycin (mtor) inhibition for treatment of mantle cell ...
6882266 - Management of early supraglottic laryngeal carcinoma by irradiation with surgery in res...
14665776 - Mediastinal lymph node staging by fdg-pet in patients with non-small cell lung cancer: ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in oncology     Volume:  24     ISSN:  1531-703X     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-03-28     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  612-22     Citation Subset:  IM    
Institut Jules Bordet, l'Université Libre de Bruxelles, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / pharmacology*,  therapeutic use
Breast Neoplasms / drug therapy*,  metabolism
Clinical Trials as Topic
Molecular Targeted Therapy
Neoplasms, Hormone-Dependent / drug therapy*,  metabolism
Quinazolines / administration & dosage
Quinolines / administration & dosage
Receptor, erbB-2 / antagonists & inhibitors,  metabolism*
Signal Transduction
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/BIBW 2992; 0/N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide; 0/Quinazolines; 0/Quinolines; 0VUA21238F/lapatinib; EC protein, human; EC, erbB-2; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detoxification and anti-nutrients reduction of Jatropha curcas seed cake by Bacillus fermentation.
Next Document:  Current treatment of acute myeloid leukemia.